| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0165-4608(02)00928-7 |
| P698 | PubMed publication ID | 12850376 |
| P2093 | author name string | Alberto Isla | |
| Juan A Rey | |||
| Dolores Arjona | |||
| Jesus Lomas | |||
| M Eva Alonso | |||
| M Josefa Bello | |||
| Pilar Gonzalez-Gomez | |||
| Jose M de Campos | |||
| Jose L Sarasa | |||
| P2860 | cites work | Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors | Q71920496 |
| Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands | Q24631957 | ||
| Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas | Q24671002 | ||
| Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents | Q27777800 | ||
| hRAD54 gene and 1p high-resolution deletion-mapping analyses in oligodendrogliomas | Q28142829 | ||
| Cancer cell cycles | Q29547756 | ||
| Cancer epigenetics comes of age | Q29617275 | ||
| Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. | Q30486834 | ||
| The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. | Q33781484 | ||
| Methylation and colorectal cancer | Q34378429 | ||
| Infrequency of p53 gene mutations in ependymomas | Q34388064 | ||
| Glutathione S-transferases: gene structure and regulation of expression | Q36764382 | ||
| Transcriptional inactivation of TP73 expression in oligodendroglial tumors | Q38290743 | ||
| CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours | Q38302408 | ||
| Changing views of the role of matrix metalloproteinases in metastasis | Q41592276 | ||
| Mutation analysis of the p73 gene in nonastrocytic brain tumours | Q41876841 | ||
| Initiation of DNA replication at CpG islands in mammalian chromosomes | Q42643271 | ||
| Mutational analysis of p73 and p53 in human cancer cell lines | Q47957541 | ||
| Methylation and silencing of the Thrombospondin-1 promoter in human cancer | Q48192580 | ||
| Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas | Q48374829 | ||
| Analysis of the NF2 gene in oligodendrogliomas and ependymomas | Q48613043 | ||
| Identification of novel regions of allelic loss in ependymomas by high-resolution allelotyping with 384 microsatellite markers | Q48805667 | ||
| Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. | Q52544855 | ||
| NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. | Q53423655 | ||
| Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. | Q55473852 | ||
| Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas--implications for tumor biology and potential clinical utility. | Q55474087 | ||
| Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. | Q55474205 | ||
| Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. | Q55474435 | ||
| CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. | Q55474994 | ||
| Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. | Q55475593 | ||
| Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. | Q55476212 | ||
| Loss of heterozygosity for distal markers on 22q in human gliomas | Q55483473 | ||
| Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia | Q56418625 | ||
| P433 | issue | 2 | |
| P921 | main subject | oligodendroglioma | Q1318384 |
| P304 | page(s) | 134-142 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Cancer Genetics and Cytogenetics | Q15753061 |
| P1476 | title | Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas | |
| P478 | volume | 144 |
| Q48239164 | A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors |
| Q55472227 | Aberrant CpG island methylation of multiple genes in ependymal tumors. |
| Q35743138 | Autophagy as a cell death and tumor suppressor mechanism |
| Q41896356 | Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events |
| Q24658389 | Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective |
| Q50977877 | Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. |
| Q34645950 | DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas |
| Q35125867 | DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma |
| Q30542025 | DNA methylation and allelic losses on chromosome arm 14q in oligodendroglial tumours |
| Q38056842 | Deregulated chromatin remodeling in the pathobiology of brain tumors |
| Q33532354 | Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. |
| Q38083798 | Emerging insights into the ependymoma epigenome |
| Q54442349 | Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients. |
| Q37301207 | Epigenetic markers in human gliomas: prospects for therapeutic intervention |
| Q37137442 | Epigenetics, nervous system tumors, and cancer stem cells |
| Q34370543 | Epigenomic profiling of men exposed to early-life stress reveals DNA methylation differences in association with current mental state |
| Q47583435 | Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses |
| Q53883940 | Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. |
| Q31019127 | Gene MGMT and oligodendrogliomas. Fundamental data and short review of the literature |
| Q34796547 | Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors. |
| Q41898533 | Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. |
| Q37355478 | Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours |
| Q36953248 | Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas |
| Q48952506 | Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? |
| Q35850389 | MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR |
| Q37412104 | Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas |
| Q24795636 | Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma |
| Q75301887 | Methylation status of TP73 in meningiomas |
| Q24683906 | Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3 |
| Q56673183 | Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3 |
| Q30438459 | Molecular genetics of ependymoma |
| Q37427424 | Molecular neuropathology of gliomas |
| Q37350203 | Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions |
| Q37148924 | Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in oligodendroglial tumors. |
| Q44327724 | O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry. |
| Q46614113 | Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression |
| Q35868124 | Pathology and molecular genetics of oligodendroglial tumors |
| Q38616800 | Pediatric Ependymoma |
| Q34132959 | Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas |
| Q30444816 | Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation |
| Q35114090 | The future of high-grade glioma: Where we are and where are we going |
| Q37523394 | The genetic and epigenetic basis of ependymoma. |
| Q55462856 | The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation. |
| Q36879301 | Therapeutic targets in the ARF tumor suppressor pathway. |
| Q38681915 | Understanding Ependymoma Oncogenesis: an Update on Recent Molecular Advances and Current Perspectives |
| Q37937061 | Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets |
| Q55465124 | [Identification of genetic alterations by multiple ligation-dependent probe amplification (MLPA) analysis in oligodendrogliomas]. |
Search more.